Be Bio has a wider pipeline with an initial focus on rare diseases and cancer. Credit: National Cancer Institute on Unsplash.

Be Biopharma (Be Bio) has raised $130m in a Series B funding round led by ARCH Venture Partners to progress its autologous and allogeneic Engineered B Cell Medicines (BeCM) platforms across various therapeutic areas.

Bristol Myers Squibb, various other new investors and current investors including Atlas Venture, RA Capital Management and Alta Partners, among others took part.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest funding takes the investment in the company to a total of more than $180m. 

As part of the financing round, ARCH Venture Partners managing director Steven Gillis will join the board of directors of Be Bio. 

ARCH co-founder and managing director Robert Nelsen and Bristol Myers Squibb Immunology, Cardiovascular and Fibrosis Thematic Research Center senior vice-president and head Robert Plenge will join Be Bio as observers.

See Also:

Be Biopharma CEO Joanne Smith-Farrell said: “The human B cell produces thousands of proteins per second. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Be Bio is harnessing this remarkable cell to engineer a new class of cellular medicines that produce durable therapeutic proteins in vivo with the potential ability to dose titrate, and re-dose when required, without the need for toxic pre-conditioning. 

“Our pipeline spans multiple therapeutic areas, and we are inspired and humbled by the potential to transform patients’ lives.”

The company works on discovering and developing BeCM and has a wider pipeline with an initial focus on rare diseases and cancer. 

BeCMs possesses the potential to be long-lasting, allogeneic, redosable and delivered without toxic conditioning. 

Be Bio intends to advance its platform into further therapeutic areas including infectious diseases, neurological conditions and autoimmune diseases.